Abstract
The cause of autism remains largely unknown because it is likely multifactorial, arising from the interaction of biologic, genetic, and environmental factors. The specific role of metabolic abnormalities also is largely unknown, but current research may provide insight into the pathophysiologic underpinnings of autism, at least in some patients. We review a number of known neurometabolic disorders identified as having an autistic phenotype. We also discuss the possible involvement of mitochondrial disorders and dysfunction as well as a theory regarding an increased vulnerability to oxidative stress, by which various environmental toxins produce metabolic alterations that impair normal cellular function. Finally, we review various strategies for metabolic work-up and treatment. Accurate diagnosis of neurometabolic disorders and a broader understanding of underlying metabolic disturbance even in the absence of known disease have important implications both for individual patients and for research into the etiology of autism.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Eisensmith RC, Goltsov AA, O’Neill C, et al.: Recurrence of the R408W mutation in the phenylalanine hydroxylase locus in Europeans. Am J Hum Genet 1995, 56:278–286.
Lowe TL, Tanaka K, Seashore MR, et al.: Detection of phenylketonuria in autistic and psychotic children. JAMA 1980, 243:126–128.
Jaeken J, Wadman SK, Duran M, et al.: Adenylosuccinase deficiency: an inborn error of purine nucleotide synthesis. Eur J Pediatr 1988, 148:126–131.
Bottini N, De Luca D, Saccucci P, et al.: Autism: evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics 2001, 3:111–113.
Manzi B, Loizzo AL, Giana G, et al.: Autism and metabolic diseases. J Child Neurol 2008, 23:307–314.
Ganesan V, Johnson A, Connelly A, et al.: Guanidinoacetate methyltransferase deficiency: new clinical features. Pediatr Neurol 1997, 17:155–157.
Weber P, Scholl S, Baumgartner ER: Outcome in patients with profound biotinidase deficiency: relevance of newborn screening. Dev Med Child Neurol 2004, 46:481–484.
Zaffanello M, Zamboni G, Fontana E, et al.: A case of partial biotinidase deficiency associated with autism. Child Neuropsychol 2003, 9:184–188.
Wevers RA, Hansen SI, van Hellenberg Hubar JL, et al.: Folate deficiency in cerebrospinal fluid associated with a defect in folate binding protein in the central nervous system. J Neurol Neurosurg Psychiatry 1994, 57:223–226.
Moretti P, Peters SU, Del Gaudio D, et al.: Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency. J Autism Dev Disord 2008, 38:1170–1177.
Pearl PL, Gibson KM, Acosta MT, et al.: Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 2003, 60:1413–1417.
Knerr I, Gibson KM, Jakobs C, Pearl PL:Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients. CNS Spectr 2008, 13:598–605.
Marcos J, Guo LW, Wilson WK, et al.: The implications of 7-dehydrosterol-7-reductase deficiency (Smith-Lemli-Opitz syndrome) to neurosteroid production. Steroids 2004, 69:51–60.
Mellon SH, Griffin LD: Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab 2002, 13:35–43.
Tierney E, Bukelis I, Thompson RE, et al.: Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:666–668.
Wallace DC: Mitochondrial diseases in man and mouse. Science 1999, 283:1482–1488.
Holt IJ, Harding AE, Petty RK, et al.: A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990, 46:428–433.
Wallace DC:Mitotic segregation of mitochondrial DNAs in human cell hybrids and expression of chloramphenicol resistance. Somat Cell Mol Genet 1986, 12:41–49.
Schon EA, DiMauro S: Mitochondrial mutations: genotype to phenotype. Novartis Found Symp 2007, 287:214–225; discussion 226–233.
Lerman-Sagie T, Leshinsky-Silver E, Watemberg N, et al.: Should autistic children be evaluated for mitochondrial disorders? J Child Neurol 2004, 19:379–381.
Pons R, Andreu AL, Checcarelli N, et al.: Mitochondrial DNA abnormalities and autistic spectrum disorders. J Pediatr 2004, 144:81–85.
Filiano JJ, Goldenthal MJ, Rhodes CH, et al.: Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome. J Child Neurol 2002, 17:435–439.
Tsao CY, Mendell JR: Autistic disorder in 2 children with mitochondrial disorders. J Child Neurol 2007, 22:1121–1123.
Oliveira G, Diogo L, Grazina M, et al.: Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol 2005, 47:185–189.
Poling JS, Frye RE, Shoffner J, et al.: Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol 2006, 21:170–172.
Lombard J: Autism: a mitochondrial disorder? Med Hypotheses 1998, 50:497–500.
Rossignol D, Bradstreet JJ: Evidence of mitochondrial dysfunction in autism and implications for treatment. Am J Biochem Biotechnol 2008, 4:208–217.
Deth R, Muratore C, Benzecry J, et al.: How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008, 29:190–201.
Valko M, Morris H, Cronin MT: Metals, toxicity and oxidative stress. Curr Med Chem 2005, 12:1161–1208.
Lanphear BP, Hornung R, Khoury J, et al.: Low-level environmental lead exposure and children’s intellectual function: an international pooled analysis. Environ Health Perspect 2005, 113:894–899.
Domingo JL: Aluminum and other metals in Alzheimer’s disease: a review of potential therapy with chelating agents. J Alzheimers Dis 2006, 10:331–341.
Mellick GD:CYP450, genetics and Parkinson’s disease: gene x environment interactions hold the key. J Neural Transm Suppl 2006, (70):159–165.
James SJ, Cutler P, Melnyk S, et al.: Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004, 80:1611–1617.
Waly M, Olteanu H, Banerjee R, et al.: Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry 2004, 9:358–370.
James SJ, Melnyk S, Jernigan S, et al.: Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:947–956.
Reed MC, Thomas RL, Pavisic J, et al.: A mathematical model of glutathione metabolism. Theor Biol Med Model 2008, 5:8.
Ming X, Stein TP, Brimacombe M, et al.: Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids 2005, 73:379–384.
Chauhan A, Chauhan V, Brown W, et al.: Oxidative stress in autism: increased lipid peroxidation and reduced levels of ceruloplasmin and transferring—the antioxidant proteins. Life Sci 2004, 75:2539–2549.
Yao Y, Walsh WJ, McGinnis WR, et al.: Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol 2006, 63:1161–1164.
Schaefer GB, Lutz RE: Diagnostic yield in the clinical genetic evaluation of autism spectrum disorders. Genet Med 2006, 8:549–556.
Filipek PA, Accardo PJ, Ashwal S, et al.: Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000, 55:468–479.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zecavati, N., Spence, S.J. Neurometabolic disorders and dysfunction in autism spectrum disorders. Curr Neurol Neurosci Rep 9, 129–136 (2009). https://doi.org/10.1007/s11910-009-0021-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-009-0021-x